Case Report: Extending dosing intervals of biologics in adults severe asthma: a case series

Background: Biological therapies have improved the control of severe asthma. However, biological therapies are expensive. Therefore, the cost-effective use of these medications after achieving improved disease control warrants consideration.

Methods: This retrospective case series analyzed 69 adult patients with asthma who received biological therapies at our department between 2009 and 2023. Among them, 11 patients underwent dosing interval extension. We collected data on their clinical characteristics, asthma control status, and changes in clinical parameters after interval extension.

Results: At the time of dosing interval extension, the mean patient age was 62.1 years, with 5 female patients. Omalizumab was used in five cases, benralizumab in five, and dupilumab in one. The dosing intervals were extended by 1.5 to 2 times. The median duration from the initiation of biologics to interval extension was 7.0 months, with 6 patients undergoing extension within the first 7 months. One year after extension, asthma exacerbation occurred in only one patient receiving omalizumab. The frequency of exacerbations and the proportion of patients receiving oral corticosteroids (OCS) were decreased. The median ACT score remained at 25, while the median daily OCS dose decreased from 5.0 mg to 4.0 mg (prednisolone equivalent). The median % predicted FEV₁ changed from 84.9% to 78.3%.

Conclusions: For patients whose asthma control improves after initiating biological therapy, extending the dosing interval may be a feasible treatment option. Given the retrospective, single-center design and small sample size, these findings are exploratory and generate hypotheses that require validation in larger, prospective studies.

Introduction

Asthma is a common chronic respiratory disease characterized by various symptoms, such as wheezing, shortness of breath, chest tightness, cough, and expiratory airflow limitation (1). Asthma affects over 300 million people worldwide and is associated with significant morbidity and mortality (2). Most patients with asthma achieve good control with medications, such as inhaled corticosteroids (ICS), bronchodilators, and anti-inflammatory agents. However, approximately 3%–10% do not achieve adequate disease control despite medications (3–7). These patients are categorized as having severe asthma. Severe asthma is defined as asthma that is uncontrolled despite adherence to an optimized high-dose combination of ICS and long-acting beta-2 agonist (LABA) therapy, and management of contributory factors, or worsens when high-dose treatment is decreased. Recent advances in our understanding of the pathogenesis of asthma have revealed that it is primarily a chronic airway inflammation involving a type 2 immune response (8). Over the last few decades, several biologics targeting type 2 inflammation, such as immunoglobulin E (IgE), interleukin-4 (IL-4), interleukin-5 (IL-5) and thymic stromal lymphopoietin (TSLP), have been introduced for the treatment of severe asthma (9). The use of these biological agents is a significant paradigm shift in asthma disease control in medicine (10).

Biological therapies are currently approved for use in patients with severe asthma that remains uncontrolled despite medium-to-high doses of ICS/LABA and additional controller medications. These treatments have been shown to improve asthma control, lung function, and asthma-related QOL, as well as reduce exacerbations and the required dose of oral corticosteroids (OCS) (9, 10). Although biologics play a significant role in the management of severe asthma, they are expensive and the medical cost burden is high. After disease control improves, it is necessary to consider drug usage methods that support responsible healthcare economics.

The GINA (Global Initiative for Asthma) guidelines for the treatment of severe asthma state (11) that when there is a good response to treatment, the first step is to reduce or discontinue OCS, and then, consider reducing the dose of inhalers and other therapeutic agents. However, dose reduction of biologic agents has not been mentioned. Two recent studies have reported on the cessation of biologics: (1) the xolair persistency of response after long-term therapy (XPORT) study and (2) the continuing long-term mepolizumab treatment (COMET) study. The XPORT study was a randomized, double-blind, placebo-controlled withdrawal study that included subjects with moderate-to-severe persistent asthma receiving long-term omalizumab (12), while the COMET study was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study that included with severe eosinophilic asthma receiving long-term mepolizumab (13). These studies reported that biologic cessation increased exacerbation and reduced asthma control. From a healthcare economics perspective, other strategies to reduce the use of biologic therapies include dose reduction and extension of dosing intervals. In Japan, with the exception of omalizumab, biologic therapies for asthma are available in a single dosage form, making dose reduction difficult. Therefore, extending the dosing interval is a practical approach for reducing treatment burden and costs in cases where the asthma is well-controlled. This study aimed to describe real-world outcomes after extending biologic dosing intervals in adults with well-controlled severe asthma.

Patients and methods

We retrospectively reviewed the medical records of 69 patients who were prescribed biologics for the treatment of severe asthma at our hospital during the 14-year period from January 2009 to March 2023. Biologics were administered to patients with severe asthma whose asthma symptoms remained uncontrolled, despite the use of medium to high-dose ICS and multiple long-term management drugs. The aim was to improve asthma symptom control and enable dose reduction or discontinuation of OCS. Inclusion criteria comprised patients whose biologic therapy dosing intervals were extended for reasons other than adverse events, such as high medical costs. Patients who had not yet reached 12 months since the extension of biologic dosing intervals were excluded. This exclusion was applied to account for the seasonal variability of asthma, as exacerbation frequency may fluctuate throughout the year. A 12-month observation period was therefore deemed necessary to adequately evaluate the outcomes of dosing interval extension. In this study, dosing intervals were extended in 11 patients, all of whom completed a 12-month follow-up period without requiring a return to the original dosing regimen. The extension of the dosing interval for biologics was defined as administering the biologic medication at a dosing interval longer than the one prescribed for each product based on health insurance system. For each biologic, the dosing interval is as follows: for omalizumab, the dosing interval is determined based on body weight and IgE levels, with doses administered every 2 to 4 weeks; for benralizumab, 30 mg is administered every 8 weeks; and for dupilumab, 300 mg is administered every 2 weeks. The extension of the dosing interval for biologics was determined through discussions between the patient and physician, based on the patient's preferences. Notably, no specific conditions, such as favorable results in pulmonary function tests or other specific evaluations, were required when extending the dosing interval. The dosing interval regimen was not determined based on pharmacokinetic considerations such as half-life, but rather was decided through a shared decision-making process between the treating physician and the patient. This process referenced extended dosing interval regimens for biologic agents used in treating other diseases. Asthma exacerbation was defined as cases requiring systemic glucocorticoids, unscheduled visits, emergency room visits, and hospitalization due to asthma attacks. We evaluated the changes in asthma control after the prolonged use of biologics at extended dosing intervals and the retention rate of the dose interval regimen. We also evaluated the asthma-related treatment changes and examination findings, and respiratory function tests performed before and after a prolonged period of being treated with biologics at extended dosing intervals.

As the study group was small (n = 11), only descriptive statistics were used. No inferential statistical tests were performed. Continuous variables are presented as median [interquartile range (IQR)], and categorical variables as numbers and percentages.

This observational study was conducted according to the ethical standards of the Declaration of Helsinki and approved by the ethical review board of Tottori University Hospital (Tottori, Japan; registration number 21A060). Written informed consent was obtained from the individuals or their legal guardian for the publication of any potentially identifiable images or data included in this article.

Results

The clinical characteristics and asthma treatment details of the 11 patients are summarized in Table 1. The median age at the time of dosing interval extension was 65 years [IQR, 47–80]; five patients (45.5%) were female, and seven (63.6%) were never smokers. Allergic rhinitis was present in six patients (54.5%), and chronic rhinosinusitis in eight (72.7%). All 11 patients received ICS/LABA combination therapy, and high-dose ICS were used in eight patients (72.7%), while five patients (45.5%) were receiving OCS, with a median daily dose of 5.0 mg [4.5–5.0] of prednisolone (PSL) equivalents. Details of the extended dosing regimens for biological therapies are presented in Table 2. The median duration from the initiation of biologics to the extension of dosing intervals was 7.0 months [6–39]. Five patients received omalizumab, five received benralizumab, and one received dupilumab. The reasons for extending the dosing interval included socioeconomic considerations (n = 7), stable asthma conditions (n = 2), and patient concerns about the side effects without actual adverse events (n = 2). Regarding socioeconomic considerations, biological therapies are extremely costly. Therefore, the extensions were implemented in response to patients' requests to reduce their financial burden.

Table 1

Table 1. Patient background at the initiation of biologics in the extended dosing interval group.

Table 2

Table 2. Types of biologics dosage, administration interval, and extended regimen.

Detailed data on the Asthma Control Test (ACT) scores, blood eosinophil counts, serum IgE levels, pulmonary function test, presence and frequency of asthma exacerbations, and the doses of ICS and OCS at three time points—before initiation of biologics, at the time of dosing interval extension, and one year after the extension—are presented in Supplementary Table S1. Summary of clinical parameters are shown in Table 3. The median ACT score was 25 [23–25] at the time of dosing interval extension and remained stable at 25 [23.5–25] after one year. The median blood eosinophil count decreased from 244 cells/μL [94–864] before biologic initiation to 134 cells/μL [0–390] at the time of interval extension, and was 222 cells/μL [0–620] after one year. The median percentage of predicted forced expiratory volume 1 (FEV₁) slight decrease from 84.9% [67.1–103.1] at the time of extension to 78.3% [75.2–106.9] after one year, while the FEV₁/ forced vital capacity (FVC) ratio showed a slight increase from 62.3% [55.0–74.2] to 63.6% [55.7–70.4]. Regarding asthma exacerbations within one year, 10 patients (90.9%) had experienced exacerbations before biologic initiation, compared to 3 patients (27.3%) at the time of dosing interval extension and only 1 patient (9.1%) one year later. The annual number of exacerbations decreased from a median of 3.0 [2.0–6.0] before biologics to 0.0 [0.0–0.0] at the time of extension, and further to 0.0 [0.0–0.0] after one year. In terms of pharmacologic therapy, the number of patients receiving OCS decreased from 5 (45.5%) before biologics to 3 (27.3%) both at the time of extension and one year later. The median daily PSL dose also decreased from 5.0 mg [5.0–5.0] at the time of extension to 4.0 mg [2.5–4.0] after one year. Similarly, the number of patients receiving high-dose ICS declined from 8 (72.7%) before biologics to 7 (63.6%) at the time of extension and 6 (54.5%) after one year. Figure 1 shows the temporal changes in ACT score, % predicted FEV₁, and daily prednisolone dose.

Table 3

Table 3. Summary of clinical parameters before biologics administration, at the time of dosing interval extension, and one year after the extension of the dosing interval.

Figure 1

Figure 1. Temporal changes in ACT score, % predicted FEV_1, and daily prednisolone dose. This figure shows the median values and ranges of the ACT score, % predicted FEV_1, and daily prednisolone dose at three time points. T0: Before starting of biologics, T1: At the start of extended biologics, T2: 1 year after extended biologics. ACT, asthma control test; FEV₁, forced expiratory volume in 1 s; PSL, prednisolone.

These findings indicate that extending the dosing interval of biologics did not lead to worsening of asthma control; rather, it was associated with a continued reduction in exacerbation frequency and allowed for tapering of concomitant asthma medications.

Discussion

This study describes the clinical characteristics of 11 severe asthma patients who underwent extended dosing intervals of biologics, as well as the findings after the dosing interval extension, asthma exacerbations, and changes in asthma treatment. Only one patient experienced an asthma exacerbation after the dosing interval extension, and the dosages of both OCS and ICS were reduced.

The efficacy of biologics is well-established, and clinical data in real-world settings are accumulating. Clinically, the REALITI-A study (14), REDES study (15), ORBEII study (16) and CROSSROAD study (17) showed that mepolizumab, benralizumab, and dupilumab were all effective for treating severe asthma. Additionally, the effectiveness of biologics for asthma treatment has been verified and demonstrated in various real-world settings (18, 19). However, biologics are expensive, and their long-term use may lead to health economics issues. Recently, cost-effectiveness has become an important consideration as biologics are costly despite their effectiveness. A recent review on the cost-effectiveness of biologics for allergic diseases concluded that, although biologics have transformed the management of severe allergic conditions, ongoing evaluation of their economic impact and sustainability is crucial (20). Therefore, the subsequent use of biologics in patients with improved asthma control is very important. The GINA guidelines recommend reducing or discontinuing OCS initially, and then, step-down treatment when asthma control improves (11). However, the guidelines did not mention biologics.

Clinical trials aimed at treatment discontinuation after improved asthma control have been conducted using omalizumab (n = 1) and mepolizumab (n = 2) (12, 13, 21). In all cases, the drugs were administered for more than one year before discontinuation. The results showed worsening asthma control and an increase in asthma exacerbation frequency among patients, indicating that the discontinuation of biologics is challenging, even after long-term administration. Discontinuation of biologics has also been investigated in patients with rheumatoid arthritis (22, 23). Evidence from these studies suggests that when biologics are introduced early after disease onset and deep remission is achieved while on medications, remission can be maintained even after discontinuation (22, 23). In contrast, many trials have shown that control worsens after the discontinuation of biologics, while other studies have shown that remission can be maintained with dose reduction (24–27). Consequently, current guidelines recommend dose reduction or extending the dosing interval of biologics, rather than discontinuation, once remission is achieved (28). Clinically, the use of dupilumab at extended dosing intervals for atopic dermatitis has been investigated. Various studies including retrospective trials, randomized controlled trials, and patient-centered trials have shown that treatment efficacy can be maintained even after extending the dosing interval (29, 30). Conversely, some studies have shown a reduction in treatment efficacy with an extension of the dosing interval (31). For example, the subcutaneous administration (300 mg every 4 weeks) of mepolizumab has been approved for treating eosinophilic granulomatosis with polyangiitis. Prospective and retrospective studies, as well as real-life setting studies, which examined the efficacy of a reduced dose (100 mg every 4 weeks) (32, 33) have all reported a remission rate of 80%–90%.

In the field of asthma, the extension of dosing intervals for biologic has also been investigated. One study compared the extension and dose reduction of omalizumab (34), one study examined the extension of dosing intervals for mepolizumab (35), and one study investigated the extension of dosing intervals for anti-IL-5 treatments (36). The study on omalizumab was a retrospective analysis, where all patients in the dose reduction group experienced exacerbations, and 27% in the dosing interval extension group experienced exacerbations, with a median time to exacerbation of 8 months. The study on mepolizumab was also a retrospective analysis, and no deterioration in ACT or lung function, nor any asthma exacerbations, were observed within one year after the extension of dosing intervals. The study on anti-IL-5 treatment was an RCT, and the exacerbation rate at 52 weeks showed that 32% of patients in the dosing interval extension group and 17% in the standard dosing group experienced exacerbations. While there was no significant difference, the dosing interval extension group tended to have more exacerbations. In this RCT, the protocol permitted a 50% extension to the dosing interval provided that asthma control was maintained. If this stability persisted, the interval could be extended by a further 50%. In cases of exacerbation, however, the interval was shortened. The extended dosing intervals used in this study were comparable to those used in our study and in previous reports. All studies included cases that did not require OCS for exacerbations. Based on the RCT and the omalizumab study, the extension of dosing intervals may not be useful, as exacerbations occurred even with extended intervals. However, the study on mepolizumab showed no exacerbations. In our study, only one exacerbation requiring OCS occurred over the course of one year, indicating a good result.

One of the distinguishing features of our study compared with previous studies is that it included a case treated with dupilumab. Furthermore, unlike other studies, we did not apply predefined criteria for selecting patients eligible for dosing interval extension. In prior studies, eligibility often required stable asthma control for at least one year before extending dosing intervals. In contrast, in our study, dosing interval extension was determined through shared decision-making between the physician and the patient, often influenced by factors such as medical costs, thereby reflecting a more real-world clinical practice. Another noteworthy aspect of our study is the variability in the timing of dosing interval extension. While previous studies typically extended intervals after at least one year of biologic therapy, in our cohort, six patients (54.5%) underwent interval extension within seven months of biologic initiation. These findings suggest that long-term administration of biologics may not be a prerequisite for maintaining asthma control after implementing extended dosing intervals.

Studies on the discontinuation of biologics have reported that asthma control deteriorates early when treatment is discontinued after achieving good asthma control through the long-term administration of mepolizumab (13, 21). Therefore, factors other than the dosing interval may influence the success or failure of extending the dosing interval. In this study, at the time of extending the dosing interval, the median ACT score was 25, indicating very good asthma control. Likewise, lung function was preserved, with a median % predicted FEV₁ of 84.9%, which falls within the normal range. For rheumatoid arthritis, extending the dosing interval or reducing the dosage of biologics is recommended after achieving remission (28). Similarly, for asthma, achieving good disease control including lung function (37–39), and introducing biological therapy at an earlier stage may be a necessary factor for the successful extension of dosing intervals. Regarding the extent of dosing interval extension, based on this study, an extension of up to twice the original interval was achievable, and this may serve as a useful reference point.

This study has several limitations. First, it was a retrospective study conducted at a single center with a small sample size, and complete longitudinal data were not available for all patients. In addition, as a case series, the study lacked a control group, which limits the ability to draw comparative conclusions and precludes direct efficacy comparisons with patients who maintain standard dosing intervals. Thus, the observed outcomes may reflect patient selection bias because only patients for whom biologics were highly effective and whose physicians deemed interval extension feasible were included. Furthermore, since this cohort primarily consisted of low-risk, highly adherent patients, it may not be representative of the general severe asthma population. Second, the dosing interval was extended based on the judgment of the attending physician in consultation with the patient, and thus, the extended dosing intervals were not consistent between patients. Therefore, only patients for whom biologics were highly effective, and whose attending physicians determined that extending the dosing interval was feasible, were included in this study. Additionally, the most appropriate dosing interval extension was not determined. Third, since this was a retrospective study, some cases had missing data regarding ACT scores, pulmonary function tests, and serum IgE levels. This missing data may have affected the interpretation of the results. Given these methodological limitations, the present findings should be considered as hypothesis-generating and require prospective validation in larger, multicenter studies.

In conclusion, extending the dosing interval of biologics may represent a viable treatment option associated with favorable clinical outcomes and potential economic benefits for patients with asthma. Notably, even a relatively short duration of biologic therapy may be sufficient for interval extension if asthma control, including pulmonary function, is well maintained. To validate these findings, large-scale prospective studies are warranted.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by the ethical review board of Tottori University Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the individual particpants for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.

Author contributions

TH: Writing – review & editing, Investigation, Conceptualization, Writing – original draft, Validation, Project administration, Data curation, Formal analysis, Methodology, Supervision. MN: Data curation, Writing – review & editing. HT: Writing – review & editing, Data curation. GI: Writing – review & editing, Data curation. HI: Data curation, Writing – review & editing. HK: Data curation, Writing – review & editing. YF: Investigation, Data curation, Writing – review & editing. TS: Writing – review & editing, Data curation, Investigation. MT: Data curation, Writing – review & editing. RO: Data curation, Writing – review & editing. MM: Writing – review & editing, Data curation, Investigation. SK: Data curation, Writing – review & editing. AY: Project administration, Data curation, Methodology, Supervision, Writing – review & editing, Writing – original draft, Investigation.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Acknowledgments

We would like to thank Editage (https://www.editage.jp) for English language editing.

Conflict of interest

TH has received speaker fees from AstraZeneca PLC., Glaxo SmithKline PLC., Novartis Pharma K.K., and Sanofi K.K. GI has received speaker fees from AstraZeneca PLC. YF has received speaker fees from AstraZeneca PLC. TS has received speaker fees from AstraZeneca PLC. and Novartis Pharma K.K. RO has received speaker fees from Novartis Pharma K.K. and Sanofi K.K. AY has received speaker fees from AstraZeneca PLC., GlaxoSmithKline PLC., Novartis Pharma K.K., and Sanofi K.K.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/falgy.2025.1635540/full#supplementary-material

Footnote

Abbreviations ACT, asthma control test; AR, allergic rhinitis; BEC, blood eosinophil counts; COPD, chronic obstructive pulmonary disease; CRS, chronic sinusitis; ECRS, eosinophilic chronic sinusitis; FEV₁, forced expiratory volume 1; FVC, forced vital capacity; GINA, global Initiative for Asthma; IL-4, interleukin-4; IL-5, interleukin-5; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; NSAIDs, non-steroidal anti-inflammatory drugs; N-ERD, NSAIDs-exacerbated respiratory disease; OCS, oral corticosteroid; PSL, prednisolone; SRT, sustained release theophylline; TSLP, thymic stromal lymphopoietin.

References

1. Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Asthma. Lancet. (2023) 401:858–73. doi: 10.1016/s0140-6736(22)02125-0

PubMed Abstract | Crossref Full Text | Google Scholar

2. Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Semin Immunopathol. (2020) 42:5–15. doi: 10.1007/s00281-020-00785-1

PubMed Abstract | Crossref Full Text | Google Scholar

3. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. (2015) 135:896–902. doi: 10.1016/j.jaci.2014.08.042

PubMed Abstract | Crossref Full Text | Google Scholar

4. Larsson K, Ställberg B, Lisspers K, Telg G, Johansson G, Thuresson M, et al. Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respir Res. (2018) 19:12. doi: 10.1186/s12931-018-0719-x

PubMed Abstract | Crossref Full Text | Google Scholar

5. Nagase H, Adachi M, Matsunaga K, Yoshida A, Okoba T, Hayashi N, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. (2020) 69:53–60. doi: 10.1016/j.alit.2019.06.003

PubMed Abstract | Crossref Full Text | Google Scholar

6. Rönnebjerg L, Axelsson M, Kankaanranta H, Backman H, Rådinger M, Lundbäck B, et al. Severe asthma in a general population study: prevalence and clinical characteristics. J Asthma Allergy. (2021) 14:1105–15. doi: 10.2147/jaa.s327659

PubMed Abstract | Crossref Full Text | Google Scholar

7. von Bülow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. (2014) 2:759–67. doi: 10.1016/j.jaip.2014.05.005

PubMed Abstract | Crossref Full Text | Google Scholar

8. Shah PA, Brightling C. Biologics for severe asthma-which, when and why? Respirology. (2023) 28:709–21. doi: 10.1111/resp.14520

PubMed Abstract | Crossref Full Text | Google Scholar

9. Mümmler C, Milger K. Biologics for severe asthma and beyond. Pharmacol Ther. (2023) 252:108551. doi: 10.1016/j.pharmthera.2023.108551

PubMed Abstract | Crossref Full Text | Google Scholar

10. Nagase H, Suzukawa M, Oishi K, Matsunaga K. Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int. (2023) 72:11–23. doi: 10.1016/j.alit.2022.11.008

PubMed Abstract | Crossref Full Text | Google Scholar

11. Diagnosis and Management of Difficult-to-treat & Severe Asthma—Global Initiative for Asthma—GINA 2024. Available online at: https://ginasthma.org/severeasthma/ (Accessed August 30, 2024).

Google Scholar

12. Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosén K, Chipps BE, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. (2017) 140:162–9.e2. doi: 10.1016/j.jaci.2016.08.054

PubMed Abstract | Crossref Full Text | Google Scholar

13. Moore WC, Kornmann O, Humbert M, Poirier C, Bel EH, Kaneko N, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. (2022) 59:2100396. doi: 10.1183/13993003.00396-2021

PubMed Abstract | Crossref Full Text | Google Scholar

14. Pilette C, Canonica GW, Chaudhuri R, Chupp G, Lee FE, Lee JK, et al. REALITI-A Study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. (2022) 10:2646–56. doi: 10.1016/j.jaip.2022.05.042

PubMed Abstract | Crossref Full Text | Google Scholar

15. Pavord I, Gardiner F, Heaney LG, Domingo C, Price RG, Pullan A, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front Immunol. (2023) 14:1150162. doi: 10.3389/fimmu.2023.1150162

PubMed Abstract | Crossref Full Text | Google Scholar

16. Padilla-Galo A, Moya Carmona I, Ausín P, Carazo Fernández L, García-Moguel I, Velasco-Garrido JL, et al. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study. Respir Res. (2023) 24:235. doi: 10.1186/s12931-023-02539-7

PubMed Abstract | Crossref Full Text | Google Scholar

17. Fukunaga K, Tagaya E, Ishida M, Sunaga Y, Koshiba R, Yokoyama A. Real-world impact of dupilumab on asthma disease burden in Japan: the CROSSROAD study. Allergol Int. (2023) 72:537–44. doi: 10.1016/j.alit.2023.04.001

PubMed Abstract | Crossref Full Text | Google Scholar

18. Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clin Exp Allergy. (2022) 52:616–27. doi: 10.1111/cea.14112

PubMed Abstract | Crossref Full Text | Google Scholar

19. Paoletti G, Pepys J, Casini M, Di Bona D, Heffler E, Goh CYY, et al. Biologics in severe asthma: the role of real-world evidence from registries. Eur Respir Rev. (2022) 31:210278. doi: 10.1183/16000617.0278-2021

PubMed Abstract | Crossref Full Text | Google Scholar

20. Wu AC, Fuhlbrigge AL, Robayo MA, Shaker M. Cost-effectiveness of biologics for allergic diseases. J Allergy Clin Immunol. (2021) 9:1107–17.e2. doi: 10.1016/j.jaip.2020.10.009

PubMed Abstract | Crossref Full Text | Google Scholar

21. Ortega H, Lemiere C, Llanos JP, Forshag M, Price R, Albers F, et al. Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial. Allergy Asthma Clin Immunol. (2019) 15:37. doi: 10.1186/s13223-019-0348-z

PubMed Abstract | Crossref Full Text | Google Scholar

22. Tanaka Y, Hirata S, Saleem B, Emery P. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol. (2013) 31:S22–7.24129132

PubMed Abstract | Google Scholar

23. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. (2010) 69:1286–91. doi: 10.1136/ard.2009.121491

PubMed Abstract | Crossref Full Text | Google Scholar

24. Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Ann Rheum Dis. (2018) 77:1268–75. doi: 10.1136/annrheumdis-2018-213416

PubMed Abstract | Crossref Full Text | Google Scholar

25. Valero M, Sánchez-Piedra C, Freire M, Colazo M, Busquets N, Meriño-Ibarra E, et al. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry. Arthritis Res Ther. (2023) 25:86. doi: 10.1186/s13075-023-03045-3

PubMed Abstract | Crossref Full Text | Google Scholar

26. Ward MM, Madanchi N, Yazdanyar A, Shah NR, Constantinescu F. Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review. Arthritis Res Ther. (2023) 25:222. doi: 10.1186/s13075-023-03199-0

PubMed Abstract | Crossref Full Text | Google Scholar

27. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. (2013) 381:918–29. doi: 10.1016/s0140-6736(12)61811-x

PubMed Abstract | Crossref Full Text | Google Scholar

28. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. (2023) 82:3–18. doi: 10.1136/ard-2022-223356

PubMed Abstract | Crossref Full Text | Google Scholar

29. Spekhorst LS, Bakker D, Drylewicz J, Rispens T, Loeff F, Boesjes CM, et al. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy. (2022) 77:3398–407. doi: 10.1111/all.15439

PubMed Abstract | Crossref Full Text | Google Scholar

30. Patruno C, Potestio L, Fabbrocini G, Napolitano M. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis. Dermatol Ther. (2022) 35:e15933. doi: 10.1111/dth.15933

PubMed Abstract | Crossref Full Text | Google Scholar

31. Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. (2020) 156:131–43. doi: 10.1001/jamadermatol.2019.3617

PubMed Abstract | Crossref Full Text | Google Scholar

32. Özdel Öztürk B, Yavuz Z, Aydın Ö, Mungan D, Sin BA, Demirel YS, et al. Effectiveness of low-dose mepolizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): a real-life experience. Int Arch Allergy Immunol. (2022) 183:1281–90. doi: 10.1159/000526410

PubMed Abstract | Crossref Full Text | Google Scholar

33. Vultaggio A, Nencini F, Bormioli S, Vivarelli E, Dies L, Rossi O, et al. Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis. Allergy Asthma Immunol Res. (2020) 12:885–93. doi: 10.4168/aair.2020.12.5.885

PubMed Abstract | Crossref Full Text | Google Scholar

34. Bolke G, Church MK, Bergmann KC. Comparison of extended intervals and dose reduction of omalizumab for asthma control. Allergo J Int. (2019) 28:1–4. doi: 10.1007/s40629-018-0087-6

Crossref Full Text | Google Scholar

35. Bolke G, Tong X, Zuberbier T, Bousquet J, Bergmann KC. Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma. World Allergy Organ J. (2022) 15:100703. doi: 10.1016/j.waojou.2022.100703

PubMed Abstract | Crossref Full Text | Google Scholar

36. Soendergaard MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, Hilberg O, Hansen S, et al. Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study). Eur Respir J. (2024) 64:2400404. doi: 10.1183/13993003.00404-202436

PubMed Abstract | Crossref Full Text | Google Scholar

37. Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. (2020) 145:757–65. doi: 10.1016/j.jaci.2019.12.006

PubMed Abstract | Crossref Full Text | Google Scholar

38. Canonica GW, Blasi F, Carpagnano GE, Guida G, Heffler E, Paggiaro P, et al. Severe asthma network Italy definition of clinical remission in severe asthma: a delphi consensus. J Allergy Clin Immunol Pract. (2023) 11:3629–37. doi: 10.1016/j.jaip.2023.07.041

PubMed Abstract | Crossref Full Text | Google Scholar

39. Blaiss M, Oppenheimer J, Corbett M, Bacharier L, Bernstein J, Carr T, et al. Consensus of an American college of allergy, asthma, and immunology, American academy of allergy, asthma, and immunology, and American thoracic society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. (2023) 131:782–5. doi: 10.1016/j.anai.2023.08.609

PubMed Abstract | Crossref Full Text | Google Scholar